Symptoms and QOL with Ceritinib in ALK plus NSCLC Patients with/without Brain Metastases

被引：0
|
作者：
Crino, Lucio [1 ]
Ahn, Myung-Ju [2 ]
De Marinis, Filippo [3 ]
Groen, H. J. M. [4 ,5 ]
Wakelee, Heather A. [6 ]
Hida, Toyoaki [7 ]
Mok, Tony [8 ]
Shaw, Alice [9 ]
Felip, Enriqueta [10 ]
Nishio, Makoto [11 ]
Scagliotti, Giorgio V. V. [12 ]
Branle, Fabrice [13 ]
Emeremni, Chetachi [14 ]
Sutradhar, Santosh [15 ]
Quadrigli, Massimiliano [13 ]
Zhang, Jie [15 ]
Spigel, David [16 ]
机构：
[1] Perugia Hosp, Perugia, Italy
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] European Inst Oncol, Thorac Oncol Div, Milan, Italy
[4] Univ Groningen, Groningen, Netherlands
[5] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands
[6] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA
[7] Aichi Canc Ctr, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[8] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
[10] Vall DHebron Univ Hosp, Barcelona, Spain
[11] Japanese Fdn Canc Res, Tokyo, Japan
[12] Univ Turin, Turin, Italy
[13] Novartis Pharma AG, Basel, Switzerland
[14] Novartis Pharma AG, E Hanover, NJ USA
[15] Novartis Pharmaceut, E Hanover, NJ USA
[16] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
ALK Inhibitor; brain metastases; Patient-reported outcomes; Ceritinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI31.13
引用
收藏
页码：S379 / S379
页数：1
相关论文
共 50 条
  • [31] Clinical experience with crizotinib in patients (pts) with advanced ALK plus non-small cell lung cancer (NSCLC) and brain metastases
    Crino, L.
    Ahn, M. J.
    Ou, S. H. I.
    Solomon, B. J.
    Costa, D. B.
    Shreeve, S. M.
    Wiltshire, R.
    Selaru, P.
    Zhou, C.
    Riely, G. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S800 - S800
  • [32] Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) metastatic to the brain
    Chow, L. Q.
    Barlesi, F.
    Bertino, E. M.
    van den Bent, M. J.
    Wakelee, H.
    Wen, P. Y.
    Chiu, C-H.
    Orlov, S.
    Majem, M.
    Chiari, R.
    McKeage, M.
    Yu, C-J.
    Hurtado, F. K.
    Arratia, P. Cazorla
    Song, Y.
    Branle, F.
    Shi, M.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2019, 30 : 602 - 603
  • [33] Importance of Capturing the Patient Experience of Overall Symptoms and HRQoL Impact in Patients With ALK plus NSCLC
    Zhu, Y.
    Lenderking, W.
    Jean-Baptiste, M.
    Scipione, F.
    Lin, H.
    Zhang, P.
    Bell, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S323 - S324
  • [34] Phase 2 study of ceritinib in ALKi-naive patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)
    Felip, E.
    Orlov, S.
    Park, K.
    Yu, C-J.
    Tsai, C-M.
    Nishio, M.
    Dols, M. C.
    McKeage, M.
    Su, W-C.
    Mok, T. S. K.
    Scagliotti, G.
    Spigel, D. R.
    Passos, V. Q.
    Chen, V.
    Munarini, F.
    Shaw, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] Cost Analysis of the Management of CNS Metastases in Patients with Advanced ALK plus NSCLC: Alectinib vs Crizotinib
    Massuti, B.
    Lazaro, M.
    Isla, D.
    Gordo, R.
    Ruiz De Alda, L.
    Ortega, N.
    Oyaguez, I.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S856 - S856
  • [36] A Phase IA Study of Ceritinib plus Trametinib in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: Preliminary Results
    Lara, M.
    Gubens, M.
    Bacaltos, B.
    Lim, S.
    Li, T.
    Gandara, D.
    Riess, J.
    Blakely, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1103 - S1103
  • [37] Treatment Patterns and Economic Burden of Brain Metastases (BM) in Patients with ALK plus mNSCLC Receiving ALK TKIs
    Le, H.
    Benjumea, D.
    Li, B.
    Shao, A.
    Rava, A.
    Silver, M.
    Vaghela, S.
    Thomaidou, D.
    Lin, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S674 - S674
  • [38] Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) NSCLC: Subgroup analysis of the ASCEND-1 trial
    Tan, Daniel Shao-Weng
    Shaw, Alice Tsang
    Mehra, Ranee
    Felip, Enriqueta
    Chow, Laura Quan Man
    Camidge, D. Ross
    Vansteenkiste, Johan F.
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin H.
    Liu, Geoffrey
    Santoro, Armando
    Geraides, Margarida
    Boral, Anthony
    Yovine, Alejandro Javier
    Kim, Dong-Wan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Felip, Enriqueta
    De Braud, Filippo G.
    Maur, Michela
    Loong, Herbert H. F.
    Shaw, Alice Tsang
    Vansteenkiste, Johan F.
    John, Tom
    Liu, Geoffrey
    Lolkema, Martijn P.
    Scott, Jeffrey W.
    Yu, Richard
    Selvaggi, Giovanni
    Mishra, Kaushal
    Lau, Yi-Yang Yvonne
    Tan, Daniel Shao-Weng
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Effect of Prophylactic Cranial Irradiation on Cognitive Function and QoL in NSCLC Patients at High Risk of Brain Metastases
    Gonzalez-Ling, A.
    Maldonado, F.
    Salinas Padilla, M.
    Arguelles, M.
    Ramirez-Tirado, L.
    Zatarain-Barron, Z.
    Barron, F.
    Cabrera-Miranda, L. A.
    Flores, D.
    Cardona, A.
    Arrieta, O.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S458 - S459
12345